Peter Philip Reese

Peter Philip Reese

Auto-generated profile, based on publicly available information

Peter Philip Reese

Vanderbilt Center for Transplant Science, Vanderbilt University Medical Center, Nashville, TN

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 July 2019 in JAMA
Verified
Journal Article
Open access
PDF file
NENwamaka Denise Eneanya
Nwamaka Denise Eneanya
WYWei Yang
Wei Yang
PRPeter Philip Reese
Peter Philip Reese
This Viewpoint questions whether the use of race as a variable in the CKD-EPI equation to estimate glomerular filtration rate (eGFR) puts some black patients at

15 June 2017 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
DGDavid S. Goldberg
David S. Goldberg
PAPeter L. Abt
Peter L. Abt
EBEmily A. Blumberg
Emily A. Blumberg
VDVivianna M. Van Deerlin
Vivianna M. Van Deerlin
MLMatthew Levine
Matthew Levine
PRPeter P. Reese
Peter P. Reese
Waiting times for kidney transplants exceed 3 to 5 years in many parts of the United States.1 Yet more than 500 high-quality kidneys from deceased donors with hepatitis C virus (HCV) infection are discarded annually.2,3 Direct-acting antiviral agents, which are associated with high HCV cure rates and manageable side effects, have created the potential to substantially increase the number of kidney transplants by making HCV-infected kidneys available to HCV-negative candidates on the waiting list.4,5

1 May 2015 in The Lancet
Verified
Journal Article
Closed access
PRPeter P Reese
Peter P Reese
NBNeil Boudville
Neil Boudville
AGAmit X Garg
Amit X Garg

4 September 2018 in Annals of Internal Medicine
Verified
Journal Article
Closed access
PDF file
PRPeter P. Reese
Peter P. Reese
PAPeter L. Abt
Peter L. Abt
EBEmily A. Blumberg
Emily A. Blumberg
VDVivianna M. Van Deerlin
Vivianna M. Van Deerlin
RBRoy D. Bloom
Roy D. Bloom
DGDavid S. Goldberg
David S. Goldberg
Organs from hepatitis C virus (HCV)–infected deceased donors are often discarded. Preliminary data from 2 small trials, including THINKER-1 (Transplanting Hepatitis C kidneys Into Negative KidnEy Recipients), suggested that HCV-infected kidneys could be safely transplanted into HCV-negative patients. However, intermediate-term data on quality of life and renal function are needed to counsel patients about risk. To describe 12-month HCV treatment outcomes, estimated glomerular filtration rate (eGFR), and quality of life for the 10 kidney recipients in THINKER-1 and 6-month data on 10 additional recipients. Open-label, nonrandomized trial. (ClinicalTrials.gov: NCT02743897) Single center. 20 HCV-negative transplant candidates. Participants underwent transplant with kidneys infected with genotype 1 HCV and received elbasvir–grazoprevir on posttransplant day 3. The primary outcome was HCV cure. Exploratory outcomes included 1) RAND-36 Physical Component Summary (PCS) and Mental Component Summary (MCS) quality-of-life scores at enrollment and after transplant, and 2) posttransplant renal function, which was compared in a 1:5 matched sample with recipients of HCV-negative kidneys. The mean age of THINKER participants was 56.3 years (SD, 6.7), 70% were male, and 40% were black. All 20 participants achieved HCV cure. Hepatic and renal complications were transient or were successfully managed. Mean PCS and MCS quality-of-life scores decreased at 4 weeks; PCS scores then increased above pretransplant values, whereas MCS scores returned to baseline values. Estimated GFRs were similar between THINKER participants and matched recipients of HCV-negative kidneys at 6 months (median, 67.5 vs. 66.2 mL/min/1.73 m2; 95% CI for between-group difference, −4.2 to 7.5 mL/min/1.73 m2) and 12 months (median, 72.8 vs. 67.2 mL/min/1.73 m2; CI for between-group difference, −7.2 to 9.8 mL/min/1.73 m2). Small trial. Twenty HCV-negative recipients of HCV-infected kidneys experienced HCV cure, good quality of life, and excellent renal function. Kidneys from HCV-infected donors may be a valuable transplant resource. Merck.

1 October 2013 in American Journal of Nephrology
Verified
Journal Article
Open access
PDF file
PRPeter P. Reese
Peter P. Reese
ACAnne R. Cappola
Anne R. Cappola
JSJustine Shults
Justine Shults
RTRaymond R. Townsend
Raymond R. Townsend
CGCrystal A. Gadegbeku
Crystal A. Gadegbeku
CICRIC Study Investigators
CRIC Study Investigators
Background: Poor physical performance and frailty are associated with elevated risks of death and disability. Chronic kidney disease (CKD) is also strongly associated with these outcomes. The risks of poor physical performance and frailty among CKD patients, however, are not well established. Methods: We measured the Short Physical Performance Battery (SPPB; a summary test of gait speed, chair raises and balance; range 0-12) and the five elements of frailty among 1,111 Chronic Renal Insufficiency Cohort participants. Adjusting for demographics and multiple comorbidities, we fit a linear regression model for the outcome of SPPB score and an ordinal logistic regression model for frailty status. Results: Median (interquartile range, IQR) age was 65 (57-71) years, median estimated glomerular filtration rate (eGFR) for non-dialysis patients was 49 (36-62) ml/min/1.73 m2, and median SPPB score was 9 (7-10). Seven percent of participants were frail and 43% were pre-frail. Compared with the SPPB score for eGFR >60 ml/min/1.73 m2, the SPPB was 0.51 points lower for eGFR 30-59; 0.61 points lower for eGFR 15-29, and 1.75 points lower for eGFR <15 (p < 0.01 for all comparisons). eGFR 30-59 (odds ratio, OR 1.45; p = 0.024), eGFR 15-29 (OR 2.02; p = 0.002) and eGFR <15 (OR 4.83; p < 0.001) were associated with worse frailty status compared with eGFR >60 ml/min/1.73 m2. Conclusions: CKD severity was associated with poor physical performance and frailty in a graded fashion. Future trials should determine if outcomes for CKD patients with frailty and poor physical performance are improved by targeted interventions.

1 April 2016 in Journal of the American Society of Nephrology
Verified
Journal Article
Open access
PDF file
PRPeter P. Reese
Peter P. Reese
MHMeera N. Harhay
Meera N. Harhay
PAPeter L. Abt
Peter L. Abt
MLMatthew H. Levine
Matthew H. Levine
SHScott D. Halpern
Scott D. Halpern
Kidney transplantation is a cost-saving treatment that extends the lives of patients with ESRD. Unfortunately, the kidney transplant waiting list has ballooned to over 100,000 Americans. Across large areas of the United States, many kidney transplant candidates spend over 5 years waiting and often die before undergoing transplantation. However, more than 2500 kidneys (>17% of the total recovered from deceased donors) were discarded in 2013, despite evidence that many of these kidneys would provide a survival benefit to wait-listed patients. Transplant leaders have focused attention on transplant center report cards as a likely cause for this discard problem, although that focus is too narrow. In this review, we examine the risks associated with accepting various categories of donated kidneys, including discarded kidneys, compared with the risk of remaining on dialysis. With the goal of improving access to kidney transplant, we describe feasible proposals to increase acceptance of currently discarded organs.